Is Emmaus Life Sciences, Inc. (EMMA) a Buy, Sell, or Hold?
OTC : EMMA
Emmaus Life Sciences, Inc.
$0.01 USD
$0.0 (-12.74%)
- Volume
- 30K
- Average Volume
- 50.11K
- Market Capitalization
- $701.88K
- P/E Ratio
- -0.08
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.02
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.08
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Willis C. Lee |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | EMMA |
| CUSIP | 29137T101 |
| CIK | 0000822370 |
| Web | https://www.emmausmedical.com |
| Phone | 310 214 0065 |
| Currency | USD |
| Employees | 34 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.47 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.08 |
| Quick Ratio | 0.06 |
| Cash Ratio | 0.02 |
Sales & Book Value
| Annual Sales | $12.45M |
| Price / Sales | 0.06 |
| Cash Flow | -0.01 |
| Price / Cash Flow | -1.11 |
| Price / Book | -0.01 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.12 |
| Trailing P/E Ratio | -0.08 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$7.49M |
| Net Margin | -70.65% |
| Pretax Margin | -70.56% |
| Return on Equity | 13.78% |
| Return on Assets | -45.45% |
Financials Score
| AltmanZ Score | -24.05 |
| Piotroski Score | 2.00 |
| Working Capital | -64.54M |
| Total Assets | 18.7M |
| Ebit | -484K |
| Market Cap | 804.36K |
| Total Liabilities | 86.56M |
Poll Results
About Emmaus Life Sciences, Inc. (OTC:EMMA) Stock
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded ... to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Emmaus Life Sciences Reports Quarterly Financial Results
2026-05-15 16:00:00
Emmaus Life Sciences, Inc. (OTCQB: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its
Emmaus Life Sciences Reports Quarterly Financial Results
2026-05-15 15:51:00
TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. Highlights “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition.
Frequently Asked Questions
-
What is the current Emmaus Life Sciences, Inc. (EMMA) stock price?
-
Emmaus Life Sciences, Inc.(OTC:EMMA) stock price is $0.01 in the last trading session. During the trading session, EMMA stock reached the peak price of $0.0172 while $0.008 was the lowest point it dropped to. The percentage change in EMMA stock occurred in the recent session was --12.74% while the dollar amount for the price change in EMMA stock was -$0.0.
-
EMMA's industry and sector of operation?
-
The OTC listed EMMA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EMMA?
-
Dale E. Short | Legal Consultant & Corporate Secretary
Charles W. Stark | Chief Science Officer and EVP of Clinical Development & Medical Affairs
Kurt H. Kruger | Consultant
Hiroko Huynh | Chief Accounting Officer
Willis C. Lee | Chief Executive Officer & Chairman of the Board -
How many employees does EMMA have?
-
Number of EMMA employees currently stands at 34. EMMA operates from 21250 Hawthorne Boulevard, Torrance, CA 90503, US.
-
Link for EMMA official website?
-
Official Website of EMMA is: https://www.emmausmedical.com
-
How do I contact EMMA?
-
EMMA could be contacted at phone #310 214 0065 and can also be accessed through its website. EMMA operates from 21250 Hawthorne Boulevard, Torrance, CA 90503, US.
-
How many shares of EMMA are traded daily?
-
The average number of EMMA shares traded daily for last 3 months was 50.11K.
-
What is the market cap of EMMA currently?
-
The market value of EMMA currently stands at $701.88K with its latest stock price at $0.01